Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of rhfgf-21 in preparation of medicine for treating dry eye syndrome

A technology of rhfgf-21, 1. rhfgf-21 is applied in the application field of rhFGF-21 in the preparation of medicaments for treating dry eye, can solve problems such as adverse reactions, and achieve the effects of reducing signs of dry eye and promoting expression

Active Publication Date: 2022-05-31
WENZHOU MEDICAL UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are corresponding solutions for different triggering factors of dry eye, but there are still many adverse reactions and other limiting factors in the treatment of anti-inflammatory drugs used on the ocular surface

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of rhfgf-21 in preparation of medicine for treating dry eye syndrome
  • Application of rhfgf-21 in preparation of medicine for treating dry eye syndrome
  • Application of rhfgf-21 in preparation of medicine for treating dry eye syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044]

[0047]

[0048]

[0055] The bagged phosphate buffered saline powder was dissolved in 2L of purified water and mixed thoroughly to obtain a 0.01M PBS buffer.

[0057] Add 10 g of paraformaldehyde powder to the PBS solution, dilute to 250 ml, and store in an airtight container. join 1

[0066] The basal tear secretion, tear break-up time (BUT) and corneal sensitivity readings of the mice are shown in Figures 1 to 3;

[0068] Mice were harvested on days 7, 14, 21, 28 and 35 of modeling. Performed with an intraperitoneal overdose of 5% chloral hydrate

[0075] 6) Slicing: fix the embedding cassette on the microtome, and slice to near the center of the cornea with a thickness of 5 μm.

[0086] 10) Cover slides: Remove the slides and wipe the xylene from the back and edges of the slides with a paper towel. take advantage of xylene

[0087] The results are shown in Figures 4 to 6. As can be seen from Figure 4, the cornea of ​​the 7D mouse has a slight staining of sodium fluor...

Embodiment 2

[0093]

[0096]

[0097]

[0104] 0.05% sodium fluorescein solution

[0107] 50 μl of goat blocking serum was taken and dissolved in 950 μl of PBS solution, and stored at -20°C until use.

[0110]

[0123] Mice were harvested on days 7 and 14 of treatment. Euthanasia was performed with an intraperitoneal overdose of 5% chloral hydrate, followed by

[0127] The 7D and 14D rhFGF-21 treatment groups, PBS control group and healthy control group mice were treated with eyeballs and

[0129] The HE staining procedure of mouse eyeball and lacrimal gland is as in Example 2.

[0133] 3) 3 times of 0.01M PBS washes, each 5min.

[0135] 5) 3 times of 0.01M PBS washes, each 5min.

[0137] 7) After removing the blocking solution with a paper towel, drop the primary antibody diluted with 1% goat blocking serum, and incubate at 4°C overnight.

[0138] 8) The next day, take out the wet box and rewarm at room temperature for 1 hour.

[0139] 9) 3 times of 0.01M PBS washes, each 5min.

[0141] 11) I...

Embodiment 4

[0152]

[0153]

[0156]

[0157]

[0165] The bagged phosphate buffered saline powder was dissolved in 2L of purified water and mixed thoroughly to obtain 0.01M PBS buffer.

[0168] Add 10 g of paraformaldehyde powder to the PBS solution, dilute to 250 ml, and store in an airtight container. join 1

[0170] 400 mL of methanol was dissolved in 100 mL of purified water to obtain an 80% methanol solution. Take 50mL 30%H

[0177]

[0178]

[0183] Treatment of dry eye mice with combined injection of rhFGF-21 and inhibitor

[0188] The 7D and 14D rhFGF-21 treated, PBS control and healthy control mice were treated with eyeballs and

[0199] (7) 3 times of 0.01M PBS washes, each 5min.

[0201] (9) After removing the blocking solution with a paper towel, drop the primary antibody diluted with 1% goat blocking serum, and incubate at 4°C overnight. and

[0209] (16) 70%, 80%, 90%, and 95% ethanol were dehydrated for 2 min each, and 100% ethanol was dehydrated twice for 1 min each.

[021...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of rhFGF-21 in preparing a medicine for treating dry eye syndrome. rhFGF‑21 improved basal tear secretion, BUT, corneal fluorescein sodium staining and corneal nerve sensitivity in a dose-dependent manner in mice with dry eye induced by scopolamine combined with dry environment, which opened up a new method for the treatment of dry eye.

Description

Application of rhFGF-21 in the preparation of medicaments for the treatment of dry eye technical field The present invention relates to the technical field of biomedicine, more specifically to rhFGF-21 in the preparation of a medicine for the treatment of dry eye applications in things. Background technique The eyeball is an important organ for sensing peripheral things, and the surface of a healthy eye is covered with glands secreted by the eyeball accessory glands. The tear film structure composed of mucin, aqueous tears and oil, this component plays a role in maintaining the normal microenvironment of the ocular surface And the effect of fully lubricating and protecting the eyeball; when any one of the components of the tear film covering the surface of the eyeball is When the homeostasis is broken and the supplement and self-repair are not timely, dry eye syndrome will be induced. The most intuitive symptom of dry eye is reflected in the change in the quality a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/18A61P27/02A61P29/00
CPCA61K38/1825A61P27/02A61P29/00
Inventor 王晓杰李校堃惠琦
Owner WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com